THE MISUSE OF CORRESPONDENT BANKING AS A CHANNEL FOR SANCTIONED ENTITIES TO ACCESS RESERVE CURRENCIES
Economic Scope · 26.10.2026 · (218) · 113-120
DOI: 10.30838/ep.218.113-120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Economic Scope, online erschienen am 26.10.2026. Verfasst von Ganna Panasenko. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The article addresses the misuse of correspondent banking by sanctioned entities utilizing shadow banking networks to access reserve currencies. Traditional discrete AML methods are inadequate against complex beneficiary concealment schemes. The study aims to uncover these exploitation mechanisms and establish a paradigm of algorithmic risk-based supervision (RegTech). The research proves that the core of modern evasion is the uncontrolled exposure of "nested relationships" via transit nodes in free economic zones. To resolve this, two metrics were developed: the Composite Reserve-Currency Clearing Exposure index and the Fee-Escalation index. Integrated into a two-tier RegTech model, they enable continuous near-real-time threat scoring. This allows regulators to transition from retrospective violation recording to proactive risk mitigation, significantly reducing compliance costs and protecting the global market from sanctions arbitrage.
Zitieren
APA
Panasenko, G. (2026). THE MISUSE OF CORRESPONDENT BANKING AS A CHANNEL FOR SANCTIONED ENTITIES TO ACCESS RESERVE CURRENCIES. Economic Scope, 113-120. https://doi.org/10.30838/ep.218.113-120
Vancouver
Panasenko G. THE MISUSE OF CORRESPONDENT BANKING AS A CHANNEL FOR SANCTIONED ENTITIES TO ACCESS RESERVE CURRENCIES. Economic Scope. 2026:113-120. doi:10.30838/ep.218.113-120
BibTeX
@article{Panasenko2026,
author = {Panasenko, Ganna},
title = {THE MISUSE OF CORRESPONDENT BANKING AS A CHANNEL FOR SANCTIONED ENTITIES TO ACCESS RESERVE CURRENCIES},
journal = {Economic Scope},
year = {2026},
number = {218},
pages = {113--120},
doi = {10.30838/ep.218.113-120}
}
EUVIMED